ISSAR Pharma

Untitled design(4)

ISSAR’s Novel Peptide Drug for Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis (RA) was observed to be the 42nd highest contributor of global physical disability. The global prevalence of rheumatoid arthritis between 1980 and 2019 was 460 per 100,000 population.

Global RA market

The RA market is estimated to reach $29.1 billion by 2029 with majority of the market driven by Janus Kinase inhibitor (JAK) class of drugs and biologics. Several companies are developing potential therapies for the treatment of RA which are in the pre-clinical or clinical stages of development.

The largest market sizes have been observed in the United States followed by Japan and Germany.  Companies like Taisho Pharmaceuticals, GlaxoSmithKline, R-Pharm, Gilead, Galapagos NV have key drug candidates in their late clinical stages or pre-clinical stages. Other companies including Merck, Pfizer, Roche, Ablynx, Novartis etc have their drug candidates which are undergoing phase II clinical trials. The various mechanisms of actions of these drugs include: TNF-alpha inhibitors, immunomodulators, cell differentiation modulators, IL-1 receptor associated inhibitors.

ISSARS IS-181 for Rheumatoid arthritis. How does it work?

ISSAR has developed a novel peptide drug for angiogenesis related diseases and inflammatory disorders. This novel peptide drug designated as IS-181 is currently under preclinical trials. It targets the VEGFR-2 which is the major receptor for angiogenesis function.

IS-181 causes modulation of VEGFR-2 receptors which are the major receptors for angiogenesis function, through down-regulation of MAPK/ p38/ ERK1/2 pathways.